Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Microbix to Manufacture Adenoviruses to Further ALS Therapy Development Institute’s Research

  • The ALS Therapy Development Institute (ALS TDI) inked a deal with Microbix Biosystems for the manufacture of adenoviral stocks to be tested in the mouse model of amyotrophic lateral sclerosis (ALS).

    “The relationship with Microbix will allow the R&D team at the ALS TDI to test dozens of adenoviral constructs to knock down the expression of genes or over-express genes that may impact disease progression in the mouse model of ALS,” says Steve Perrin, CSO at the ALS TDI.

    Under the terms of the one-year contract, Microbix will use its technology to produce, purify, and characterize various adenoviruses created to carry therapies to sites of ALS pathology.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »